Eterna Therapeutics Inc. financial data

Symbol
ERNA on Nasdaq
Industry
Pharmaceutical Preparations
Location
1035 Cambridge Street, Suite 18 A, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Brooklyn ImmunoTherapeutics, Inc. (to 10/14/2022), NTN BUZZTIME INC (to 3/23/2021), NTN COMMUNICATIONS INC (to 12/20/2005)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 71 % -31.9%
Debt-to-equity -378 % -193%
Return On Equity 326 %
Return On Assets -117 % -101%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 51.4M shares +850%
Common Stock, Shares, Outstanding 5.41M shares +0.02%
Entity Public Float 9.7M USD -59.2%
Common Stock, Value, Issued 27K USD 0%
Weighted Average Number of Shares Outstanding, Basic 5.41M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 5.41M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 487K USD +855%
Cost of Revenue -60K USD -150%
Research and Development Expense 1.69M USD -69%
General and Administrative Expense 15.9M USD +22.6%
Operating Income (Loss) -18.7M USD +6.79%
Nonoperating Income (Expense) -26.2M USD -18405%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -44.9M USD -125%
Income Tax Expense (Benefit) 15K USD -63.4%
Net Income (Loss) Attributable to Parent -44.9M USD -125%
Earnings Per Share, Basic -8.31 USD/shares -116%
Earnings Per Share, Diluted -8.31 USD/shares -116%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.26M USD -6.31%
Assets, Current 4.73M USD -32.7%
Property, Plant and Equipment, Net 105K USD -39.3%
Operating Lease, Right-of-Use Asset 719K USD -97.9%
Goodwill 2.04M USD 0%
Other Assets, Noncurrent 120K USD -97%
Assets 7.72M USD -85.2%
Accounts Payable, Current 2.19M USD +49.8%
Employee-related Liabilities, Current 108K USD -10.7%
Accrued Liabilities, Current 1.17M USD -76.8%
Liabilities, Current 9.95M USD +3.39%
Operating Lease, Liability, Noncurrent 534K USD -98.5%
Other Liabilities, Noncurrent 84K USD
Liabilities 53.1M USD +9.09%
Retained Earnings (Accumulated Deficit) -226M USD -24.9%
Stockholders' Equity Attributable to Parent -45.4M USD -1374%
Liabilities and Equity 7.72M USD -85.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.75M USD +38.1%
Net Cash Provided by (Used in) Financing Activities 1.39M USD
Net Cash Provided by (Used in) Investing Activities -97K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 5.41M shares +0.02%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.26M USD -50.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 18.3M USD +13.3%
Deferred Tax Assets, Gross 29.3M USD +76.9%
Operating Lease, Liability 735K USD -98%
Payments to Acquire Property, Plant, and Equipment 101K USD
Lessee, Operating Lease, Liability, to be Paid 855K USD -98.7%
Property, Plant and Equipment, Gross 607K USD +126%
Operating Lease, Liability, Current 201K USD -82.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 267K USD -95.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 274K USD -95.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure -15.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 120K USD -99.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 163K USD -97.4%
Preferred Stock, Shares Issued 156K shares 0%
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 393K USD +225%
Lessee, Operating Lease, Liability, to be Paid, Year Four 82K USD -98.7%
Additional Paid in Capital 180M USD -2.17%
Preferred Stock, Shares Outstanding 156K shares 0%
Depreciation, Depletion and Amortization 39K USD +85.7%
Deferred Tax Assets, Net of Valuation Allowance 11M USD +2673%
Share-based Payment Arrangement, Expense 1.28M USD -13.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%